Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12716 | 0.97 | HRH3 (0.48) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL8074673 | 0.97 | HRH3 (0.48) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL24724037 | 0.97 | HRH3 (0.48) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL441047 | 0.94 | — | — | |
| SCHEMBL12000726 | 0.88 | — | — | |
| SCHEMBL6057217 | 0.88 | ALOX15 (0.38) | — | |
| SCHEMBL20438382 | 0.88 | ALOX15 (0.38) | — | |
| Acetic Acid SCHEMBL31035858 | 0.87 | ALDH1A1 (0.44) | MAPTKDM4EALDH1A1MCL1L3MBTL1 | |
| SCHEMBL439509 | 0.84 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL17806050 | 0.84 | CHKA (0.43) | PRMT6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202848-B2 | Phosphoramidite activator | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-114555617-B | Phosphoramidite activators | 富士胶片和光纯药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-4047004-B1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2001051527-A1 | PROCATALYSTS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051526-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000075203-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075202-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075204-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000052068-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0264499-B1 | SULFONATED POLY(ARYL ETHER) RESINS AND INTERMEDIATE SILYL SULFONATE DERIVATIVES; METHODS OF MAKING THEM, AND MEMBRANES FORMED FROM THE RESINS | AMOCO CORPORATION (an Indiana corp.) (US) | 1990-08-01 | — | — | EP | disclosed |
| EP-0264499-A1 | Sulfonated poly(aryl ether) resins and intermediate silyl sulfonate derivatives; methods of making them, and membranes formed from the resins | AMOCO CORPORATION (an Indiana corp.) (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4625000-A | SULFONATED WITH SILYL HALOSULFONATE THEN CLEAVAGE OF SILYL GROUP | UNION CARBIDE CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| US-4450246-A | TERTIARY AMINE SALT | W. R. GRACE & CO. (US) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | CARM1 2953/4885PRMT6 2886/4885PRMT8 3444/4885 |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | ITPA, INPP5D, INPP5B | CARM1 2442/4885PRMT6 2943/4885PRMT8 1804/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | CARM1 4365/4885PRMT6 3088/4885PRMT8 1608/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | CARM1 2649/4885PRMT6 1784/4885PRMT8 2659/4885 |
| US-12202848-B2 | Phosphoramidite activator | ITPA, INPP5D, INPP5B | CARM1 2442/4885PRMT6 2943/4885PRMT8 1804/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CARM1 2000/4885PRMT6 1285/4885PRMT8 1774/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CARM1 216/4885PRMT6 185/4885PRMT8 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.